Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OLT1177 in Healthy Subjects
NCT02134964Phase 1Completed
- Sponsor
- Olatec Therapeutics LLC
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout, osteoarthritis (OA) and heart failure (HF) comparing OLT1177 Capsules with Placebo Capsules (2 arms). Primary endpoint: Recording of adverse events. Started Jun 2014; status: completed.
02
Drugs
dapansutrile
03
Conditions
goutosteoarthritis (OA)heart failure (HF)
Beyond the preview
Go deeper on NCT02134964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134964.